COSCIENS Biopharma Inc. Shares Top-Line Results from Phase 3 DETECT-Trial
- The top-line data revealed unexpected results that require further clarification; the primary endpoint was not met according to the trial protocol.
- Macimorelin prompted a strong release of growth hormone following stimulation.
- The safety of macimorelin has been confirmed in the pediatric population.
Overview of the Study
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”) has recently released findings from its Phase 3 safety and efficacy study, known as the DETECT-trial. This trial focused on evaluating macimorelin for diagnosing Childhood Onset Growth Hormone Deficiency (CGHD). While the results indicate that macimorelin successfully stimulated growth hormone release, it did not meet the primary efficacy endpoint specified in the trial protocol.
Initial Findings
The study compared the macimorelin test to traditional growth hormone stimulation tests, including arginine and clonidine. An initial review of the findings suggests that these standard stimulant tests may have resulted in a high false positive rate, which likely impacted macimorelin’s ability to meet the primary efficacy endpoint. As a result, further analysis and clarification are necessary to fully understand these unexpected outcomes.
Design and Methodology of the Trial
The DETECT-trial was a comprehensive, international, multicenter study that involved 102 participants aged between 3 and 17 years. Macimorelin was administered at a dosage of 1.0 mg/kg body weight, with various assessments conducted during scheduled visits aimed at evaluating pharmacokinetic (PK) and pharmacodynamic (PD) responses. An independent expert panel was tasked with determining the final growth hormone deficiency status for each participant, based on the collected medical data and results from standard tests.
Insights on Safety and Efficacy
Nicola Ammer, Chief Medical Officer of COSCIENS, stated that the DETECT-trial confirmed the excellent safety profile of macimorelin, consistent with previous studies involving adult Growth Hormone Deficiency (AGHD). However, it was surprising to find that many subjects deemed ill by traditional tests showed significant growth hormone stimulation after receiving macimorelin. The team intends to conduct a detailed analysis to uncover the reasons behind these results.
Study Outcome Implications
The trial established a notably high optimal growth hormone cut-off point of 25.59 ng/mL, which significantly surpasses the standard range of 7-10 ng/mL recommended in current medical guidelines. This elevated cut-off raises concerns regarding the sensitivity and specificity of macimorelin as a diagnostic tool, which are critical factors in assessing test performance and reliability in clinical applications.
Future Directions
Moving forward, COSCIENS plans to present the DETECT-trial's top-line data to healthcare authorities and will assess the implications for macimorelin's future use. The product is already approved in the USA and is marketed in Europe for AGHD. The Company remains dedicated to prioritizing ongoing projects and directing resources toward initiatives that promise growth and innovation in the biopharmaceutical sector.
About Macimorelin
Macimorelin, known as Macrilen® in the U.S. and GHRYVELIN® in Europe, is a crucial oral medication approved for adult growth hormone deficiency. This peptidomimetic molecule stimulates the secretion of growth hormone from the pituitary gland and plays a vital role in improving the accuracy of AGHD diagnosis.
About COSCIENS Biopharma Inc.
COSCIENS is a prominent specialty biopharmaceutical company focused on developing and commercializing a variety of pharmaceutical and diagnostic products. Their innovative portfolio includes macimorelin, the first oral test approved by health authorities for diagnosing adult growth hormone deficiency. Additionally, COSCIENS is engaged in developing new therapeutic assets and extraction technologies from natural sources, contributing to the production of active ingredients used in leading cosmeceutical brands.
Frequently Asked Questions
What are the main results of the DETECT-trial?
The DETECT-trial indicated that while macimorelin effectively stimulates growth hormone release, it did not meet the primary efficacy endpoint as outlined in the study protocol.
What does the surprising cut-off point of 25.59 ng/mL mean?
This elevated cut-off point suggests potential challenges with sensitivity and specificity when diagnosing childhood-onset growth hormone deficiency using macimorelin.
What is macimorelin used for?
Macimorelin is an oral medication utilized for diagnosing adult growth hormone deficiency and is crucial for ensuring the accuracy of hormone level assessments.
What is the next step for COSCIENS after the trial results?
COSCIENS intends to conduct further analysis of the DETECT-trial data and engage with health authorities to discuss future directions regarding the use of macimorelin.
How does COSCIENS Biopharma contribute to the healthcare market?
COSCIENS focuses on developing innovative pharmaceutical and diagnostic products that address significant unmet medical needs while also exploring sustainable extraction technologies from plant resources.
